UCARTTX1

UCARTTX1 is an investigational, allogeneic, gene‑edited chimeric antigen receptor T‑cell (CAR‑T) therapy candidate, designed as an off‑the‑shelf T‑cell product derived from healthy donors and edited ex vivo to redirect T‑cell cytotoxicity against a tumor‑associated antigen while minimizing graft‑versus‑host reactivity. It is conceptually related to Cellectis’ UCART platform (e.g., UCARTCS1, UCART19, UCART22), which uses TALEN gene editing to disrupt endogenous T‑cell receptor expression and specific target antigens before introducing a CAR construct, enabling scalable manufacturing of non‑alloreactive CAR‑T cells for hematologic malignancies.[1][5] Publicly available sources as of now do not provide detailed target, indication, or sponsor information specific to UCARTTX1; it appears to be an internal or early‑stage code name within the broader UCART gene‑edited CAR‑T portfolio.